Climate Change Data

Environmental Metrics

ESG Focus Areas

• Access to healthcare
• Corporate governance
• Financial performance and business strategy
• Product safety and quality
• Research and development – products and services innovation
• Employee recruitment, development and retention
• Supply chain management
• Ethical marketing
• Bribery, corruption and anti-competitive behaviour

Environmental Achievements

• Waste recycling rate of 43%
• Reductions in energy consumption intensity, greenhouse gas emission intensity, and water consumption intensity compared with prior years

Social Achievements

• Employee engagement score of 75% favourable (three points above IBM’s global norm)
• Decreases in lost time injury frequency rate (26%), days lost frequency rate (53%), and medical treatment rate (17%)
• No employee or contractor work-related fatalities
• US$39.5 million in global community investment
• 99% of plasma donors willing to donate again, 96% willing to refer a friend

Governance Achievements

• No breaches of product marketing and promotional activities by the US FDA, EMA or Medicines Australia
• No allegations resulting in regulatory action or action by law enforcement authorities
• No instances of bribery or corruption reported

Climate Goals & Targets

Environmental Challenges

• Decreased waste recycling rate compared to the previous year
• Maintaining employee engagement and work/life balance
• Assessing supplier performance against environmental and social aspects
• Managing risks associated with bribery and corruption in a diverse and complex marketplace

Mitigation Strategies

• Implementation of a Global CSL EHS2 Management System Standard
• Global project to evaluate options for a global recognition platform
• Investment in additional staff to more effectively engage suppliers in risk reduction
• Implementation of a standardised questionnaire to assess bribery and corruption risk
• Updated Code of Responsible Business Practice and Global Serious Complaints Policy

Supply Chain Management

Supplier Audits: 489

Responsible Procurement

• Global risk management framework
• Qualification of alternative suppliers
• Maintaining safety stock
• Rigorous supplier relationship and performance management

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: GRI

Third-party Assurance: Ernst & Young (limited assurance)

UN Sustainable Development Goals

• Goal 3: Good Health and Well-being
• Goal 8: Decent Work and Economic Growth
• Goal 9: Industry, Innovation and Infrastructure
• Goal 13: Climate Action

CSL's activities support these goals through the development and delivery of innovative medicines, investment in R&D, commitment to employee well-being, and environmental sustainability initiatives.

Sustainable Products & Innovation

• HAEGARDA
• PRIVIGEN
• HIZENTRA

Awards & Recognition

• One of the world’s top 50 employers by Forbes
• One of Australia’s top 20 most innovative companies
• Job & Family Employer award (Marburg site)

Environmental Metrics

ESG Focus Areas

• Environment
• Social
• Governance
• Sustainable Workforce

Environmental Achievements

• Reduced Scope 1 and 2 greenhouse gas emissions compared to the prior year due to increased renewable energy in Europe, despite acquisition of CSL Vifor and increased production.
• CSL Seqirus' new cell-based influenza vaccine manufacturing facility designed with best-in-class sustainable features (renewable energy, electrification, heat recovery, water reuse).
• New global headquarters achieved a five-star Green Star rating.
• Ethanol recovery at CSL Behring, Broadmeadows, Australia, reduced liquid industrial waste by ~9,500 tons/year and eliminated over 270 truck movements per year.

Social Achievements

• 94% of plasma donors willing to donate again and 91% willing to refer a friend.
• Implementation of new plasma collection system (Rika) expected to improve donor comfort and reduce donation time.
• US$13.7 million investment in humanitarian access programs and product support initiatives.
• Donation of 100 million IUs of coagulation factor therapy per year for five years to the WFH Humanitarian Aid Program.
• US$42.6 million in global community investment.

Governance Achievements

• 475 regulatory inspections with no critical findings preventing product release or license suspension.
• Introduction of a global sustainability measure (environment) into the STI plan with a 5% weighting.

Climate Goals & Targets

Environmental Challenges

• Increased Scope 1 and 2 emissions due to acquisition and increased production at some locations.

Mitigation Strategies

• Increased proportion of purchased electricity from renewable sources in Europe.
• Implementation of a portfolio and program governance system to support the 2030 emission reduction target.
• Dedicated supplier engagement program to encourage science-based targets.

Supply Chain Management

Responsible Procurement

• Revised procurement standards and award criteria
• Supplier enablement through advocacy and education
• Strategic partnerships to innovate and collaborate

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: SBTi

Third-party Assurance: Ernst & Young (limited assurance)

Sustainable Products & Innovation

• New cell-based influenza vaccine manufacturing facility